Natera, Inc.
NTRA
Services-Medical Laboratories
Mkt Cap
$13.24BPE
-36.22Debt
$363.7MCash
$813.8MEV
$12.79BFCF
-$187MP/E Ratio
-36.22Debt
$363.7MCash
$813.8MEV
$12.79BFCF
-$187MCharts data: {"Earnings":[{"time":"2014-12-30","value":-5152000},{"time":"2015-12-30","value":-70275000},{"time":"2016-12-30","value":-95765000},{"time":"2017-12-30","value":-136314000},{"time":"2018-12-30","value":-128154000},{"time":"2019-12-30","value":-124827000},{"time":"2020-12-30","value":-229743000},{"time":"2021-12-30","value":-471716000},{"time":"2022-12-30","value":-547799000},{"time":"2023-12-30","value":-434801000}],"Sales":[{"time":"2014-12-30","value":159289000},{"time":"2015-12-30","value":190355000},{"time":"2016-12-30","value":217074000},{"time":"2017-12-30","value":210939000},{"time":"2018-12-30","value":257654000},{"time":"2019-12-30","value":302328000},{"time":"2020-12-30","value":391005000},{"time":"2021-12-30","value":625486000},{"time":"2022-12-30","value":820222000},{"time":"2023-12-30","value":1082571000}],"Net Margins":[{"time":"2014-12-30","value":-0.032343727438806195},{"time":"2015-12-30","value":-0.3691786399096425},{"time":"2016-12-30","value":-0.44116292140007557},{"time":"2017-12-30","value":-0.646224737957419},{"time":"2018-12-30","value":-0.4973879699131393},{"time":"2019-12-30","value":-0.4128860046042709},{"time":"2020-12-30","value":-0.5875704914259409},{"time":"2021-12-30","value":-0.7541591658326485},{"time":"2022-12-30","value":-0.6678667482705901},{"time":"2023-12-30","value":-0.4016373983784897}],"Assets":[{"time":"2014-12-30","value":123623000},{"time":"2015-12-30","value":265240000},{"time":"2016-12-30","value":210680000},{"time":"2017-12-30","value":178776000},{"time":"2018-12-30","value":268171000},{"time":"2019-12-30","value":582656000},{"time":"2020-12-30","value":932153000},{"time":"2021-12-30","value":1236487000},{"time":"2022-12-30","value":1394474000},{"time":"2023-12-30","value":1441699000}],"Stockholders Equity":[{"time":"2014-12-30","value":-171335000},{"time":"2015-12-30","value":184765000},{"time":"2016-12-30","value":106476000},{"time":"2017-12-30","value":-10370000},{"time":"2018-12-30","value":32162000},{"time":"2019-12-30","value":278711000},{"time":"2020-12-30","value":486236000},{"time":"2021-12-30","value":653304000},{"time":"2022-12-30","value":705744000},{"time":"2023-12-30","value":765327000}],"ROE":[{"time":"2014-12-30","value":0.030069746403245105},{"time":"2015-12-30","value":-0.38034800963385923},{"time":"2016-12-30","value":-0.8994045606521658},{"time":"2017-12-30","value":13.1450337512054},{"time":"2018-12-30","value":-3.98464025869038},{"time":"2019-12-30","value":-0.44787252745675626},{"time":"2020-12-30","value":-0.4724927812831629},{"time":"2021-12-30","value":-0.7220467041377368},{"time":"2022-12-30","value":-0.7762007186741935},{"time":"2023-12-30","value":-0.5681244748976582}],"ROA":[{"time":"2014-12-30","value":0.005379257905082388},{"time":"2015-12-30","value":-0.22559945709546073},{"time":"2016-12-30","value":-0.45387791911904307},{"time":"2017-12-30","value":-0.7496923524410435},{"time":"2018-12-30","value":-0.4274436833214628},{"time":"2019-12-30","value":-0.19958088477592267},{"time":"2020-12-30","value":-0.23201877803321988},{"time":"2021-12-30","value":-0.37863236734393485},{"time":"2022-12-30","value":-0.3879885892458375},{"time":"2023-12-30","value":-0.3014013327331156}]}
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
![LH Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>LH</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -37% | -44% | -65% | -50% | -41% | -59% | -75% | -67% | -40% | -30% |
| ROA | -23% | -45% | -75% | -43% | -20% | -23% | -38% | -39% | -30% | -25% |
| ROE | -38% | -90% | 1.3K% | -400% | -45% | -47% | -72% | -78% | -57% | -46% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -55.36%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -1.29%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -32.12%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -0.23%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -116.19%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +45.28%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | -0.92 | -0.51 | -1.15 | -1.66 | -1.83 | -1.25 | -0.90 | -0.77 | -1.29 | -1.94 |
| Debt Equity | 0.23 | 0.47 | -11.88 | 3.84 | 0.45 | 0.52 | 0.52 | 0.52 | 0.48 | 0.46 |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | - |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -1.94.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is 0.15.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 26% | 33% | 40% | 32% | 3.9% |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 33% | 88% | 16% | 8.4% | -22% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +33.26%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +3.9%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +27.68%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +88.5%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -21.5%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +30.9%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.